Royal Bank of Canada’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $302K | Buy |
17,447
+4,801
| +38% | +$65.8K | ﹤0.01% | 4715 |
|
|
2026
Q1 | $157K | Buy |
12,646
+3,191
| +34% | +$42.8K | ﹤0.01% | 4848 |
|
|
2025
Q4 | $118K | Sell |
9,455
-1,529,485
| -99% | -$17.5M | ﹤0.01% | 5109 |
|
|
2025
Q3 | $15.4M | Buy |
1,538,940
+299
| +0% | +$2.68K | ﹤0.01% | 1855 |
|
|
2025
Q2 | $12.4M | Buy |
1,538,641
+1,528,625
| +15,262% | +$11.5M | ﹤0.01% | 1867 |
|
|
2025
Q1 | $84K | Sell |
10,016
-5,706
| -36% | -$47.6K | ﹤0.01% | 5319 |
|
|
2024
Q4 | $124K | Sell |
15,722
-22,117
| -58% | -$186K | ﹤0.01% | 5198 |
|
|
2024
Q3 | $314K | Buy |
37,839
+4,438
| +13% | +$34.7K | ﹤0.01% | 4468 |
|
|
2024
Q2 | $212K | Sell |
33,401
-70,889
| -68% | -$450K | ﹤0.01% | 4716 |
|
|
2024
Q1 | $632K | Buy |
104,290
+32,445
| +45% | +$183K | ﹤0.01% | 3802 |
|
|
2023
Q4 | $436K | Buy |
71,845
+14,517
| +25% | +$64.7K | ﹤0.01% | 4387 |
|
|
2023
Q3 | $242K | Buy |
57,328
+7,749
| +16% | +$28.9K | ﹤0.01% | 4624 |
|
|
2023
Q2 | $153K | Buy |
49,579
+5,993
| +14% | +$12.8K | ﹤0.01% | 4978 |
|
|
2023
Q1 | $60K | Sell |
43,586
-11,574
| -21% | -$23K | ﹤0.01% | 5519 |
|
|
2022
Q4 | $109K | Buy |
55,160
+16,885
| +44% | +$37.8K | ﹤0.01% | 5380 |
|
|
2022
Q3 | $77K | Buy |
38,275
+835
| +2% | +$2.34K | ﹤0.01% | 5482 |
|
|
2022
Q2 | $119K | Sell |
37,440
-5,548
| -13% | -$20.1K | ﹤0.01% | 5216 |
|
|
2022
Q1 | $180K | Sell |
42,988
-13,093
| -23% | -$58K | ﹤0.01% | 5174 |
|
|
2021
Q4 | $269K | Buy |
56,081
+3,082
| +6% | +$15.4K | ﹤0.01% | 5044 |
|
|
2021
Q3 | $283K | Buy |
52,999
+3,995
| +8% | +$20.1K | ﹤0.01% | 4841 |
|
|
2021
Q2 | $251K | Sell |
49,004
-13,504
| -22% | -$76.8K | ﹤0.01% | 4875 |
|
|
2021
Q1 | $421K | Sell |
62,508
-1,548
| -2% | -$8.58K | ﹤0.01% | 4333 |
|
|
2020
Q4 | $292K | Buy |
64,056
+351
| +0.6% | +$1.55K | ﹤0.01% | 4567 |
|
|
2020
Q3 | $247K | Buy |
63,705
+16,930
| +36% | +$72.4K | ﹤0.01% | 4388 |
|
|
2020
Q2 | $222K | Sell |
46,775
-8,360
| -15% | -$34.4K | ﹤0.01% | 4381 |
|
|
2020
Q1 | $191K | Sell |
55,135
-86,286
| -61% | -$365K | ﹤0.01% | 4362 |
|
|
2019
Q4 | $682K | Buy |
141,421
+66,477
| +89% | +$231K | ﹤0.01% | 3750 |
|
|
2019
Q3 | $218K | Sell |
74,944
-52,866
| -41% | -$184K | ﹤0.01% | 4399 |
|
|
2019
Q2 | $916K | Buy |
127,810
+3,704
| +3% | +$37.9K | ﹤0.01% | 3376 |
|
|
2019
Q1 | $1.76M | Buy |
124,106
+67,353
| +119% | +$890K | ﹤0.01% | 2800 |
|
|
2018
Q4 | $768K | Sell |
56,753
-20,190
| -26% | -$364K | ﹤0.01% | 3371 |
|
|
2018
Q3 | $1.71M | Buy |
76,943
+9,111
| +13% | +$192K | ﹤0.01% | 2958 |
|
|
2018
Q2 | $1.11M | Buy |
+67,832
| New | +$1.19M | ﹤0.01% | 3146 |
|
Other funds holding AMRX
TGA
RCMNY
Royal Bank of Canada's AMRX Position: Q2 2026 in Review
Royal Bank of Canada increased its Amneal Pharmaceuticals (AMRX) stake by 38% in Q2 2026, buying an estimated $65.8K and bringing the position to 17,447 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #4715.
Royal Bank of Canada first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. The position peaked at $15.4M in Q3 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Royal Bank of Canada held 17,447 shares of Amneal Pharmaceuticals worth $302K as of Q2 2026.
- Royal Bank of Canada bought 4,801 Amneal Pharmaceuticals shares in Q2 2026, an estimated $65.8K.
- Amneal Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4715 holding.
- Royal Bank of Canada first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- Royal Bank of Canada's Amneal Pharmaceuticals position peaked at $15.4M in Q3 2025.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.